<DOC>
	<DOC>NCT02667223</DOC>
	<brief_summary>This is a Phase 1, open-label, single-dose, randomized, dose escalation study in healthy and hypercholesterolemic subjects. Each subject will receive 1 of 5 treatments as a single subcutaneous injection. Subjects will remain confined at the research clinic for approximately 2 days. After discharge, subjects will return to the research clinic 15 times during 12 weeks.</brief_summary>
	<brief_title>Pharmacokinetic and Pharmacodynamic Study of Bococizumab Alone and When Combined With Recombinant Human Hyaluronidase</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>Healthy and hypercholesterolemic subjects between the ages of 18 and 65 years. Healthy subjects must have fasting LDLC &gt;/= 70 to &lt;/= 190 mg/dL at two qualifying visits. Hypercholesterolemic subjects must be on a stable daily dose of statin for at least 45 days before dosing and fasting LDLC must be &gt;/= 70 mg/dL. Use of prescription or nonprescription drugs within 7 days or 5 halflives (whichever) is longer prior to the first dose of study medication. For hypercholesterolemic subjects the use of statin class medication is allowed. Prior exposure to bococizumab (also known as PF04950615 or RN316) or other investigational PCSK9 inhibitors. Treatment with monoclonal antibodies within 6 months or 5 halflives (whichever is longer) before dosing.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>RN316</keyword>
	<keyword>recombinant human hyaluronidase</keyword>
</DOC>